Skip to Main Content

Paper Details

Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
Mayo Clin Proc
2
2022

Datasets

Release 1.2